Vitamin D may slow progression of low-grade prostate tumors
the ONA take:
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery, new research presented at the 249th National Meeting & Exposition of the American Chemical Society (ACS) in Denver, Colorado has shown.
For the randomized, controlled clinical trial, researchers assigned 37 men with low-grade prostate cancer undergoing elective prostatectomies to receive either 4,000U of vitamin D daily or placebo during the 60-day waiting period prior to surgery. The patients' prostate glands were then removed and examined.
Results showed that men who received vitamin D showed improvements in their prostate tumors while those in the placebo group experienced no changes or their tumors got worse.
The findings suggest that vitamin D supplementation, well below pharmacological levels, may improve less aggressive prostate cancer by decreasing inflammation. It is not clear yet whether vitamin D prevents or treats prostate cancer, but it can prevent lower-grade tumors from becoming aggressive.
Vitamin D supplements may slow or even reverse the progression of low-grade prostate cancer without the use of radiation or surgery.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Risk of Second Cancers Increased in Hodgkin Lymphoma Survivors
- ONS Partners with ASCO CancerLinQ to Launch CancerLinQ® Ambassadors Program
- Characteristics of Clinical Trials and Barriers to Patient Enrollment Identified
- Exercise Improves Coping While Undergoing Chemotherapy for Advanced GI Cancer
- Genetic Similarity to BRCA1/BRCA2 Mutations May Impact Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|